Log In Sign up
The largest database of trusted experimental protocols

Mission trc2 plko 5 puro non mammalian shrna control plasmid dna

Manufactured by Merck Group
Visit Supplier

The MISSION® TRC2 pLKO.5-puro Non-Mammalian shRNA Control Plasmid DNA is a laboratory reagent designed for use in shRNA-based gene silencing experiments. It serves as a control plasmid in such studies.

Automatically generated - may contain errors

Lab products found in correlation

Lentiviral packaging mix, by Merck Group (2 mentions) Plko puro shrna constructs, by Merck Group (2 mentions)

Spelling variants of this product

MISSION shRNA (251 citations) Control shRNA (39 citations) MISSION® shRNA Plasmid DNA (24 citations) ShRNA plasmids (15 citations) PLKO.5-Puro (2 citations) PLKO shRNAs (2 citations)

2 protocols using mission trc2 plko 5 puro non mammalian shrna control plasmid dna

1

Lentiviral Transduction for Gene Knockdown

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lentiviruses were produced by co-transfection HEK293LTX cells with the MISSION® TRC2 pLKO.5-puro Non-Mammalian shRNA Control Plasmid DNA or with the pLKO-puro shRNA constructs (Sigma, shRNA sequences are available in Table S3) and the Lentiviral Packaging Mix (psPAX2 and pMD2.G). U2OS and NCIH1975 cells were transduced by the lentivirus, and cells with stable knockdowns were selected using puromycin (2 μg/ml for U2OS and 1 μg/ml for NCIH1975). The knockdown of RUNX1 and SNAI1 in stable cell lines was confirmed by quantitative real-time PCR.
Peng X., Chen Z., Farshidfar F., Xu X., Lorenzi P.L., Wang Y., Cheng F., Tan L., Mojumdar K., Du D., Ge Z., Li J., Thomas G.V., Birsoy K., Liu L., Zhang H., Zhao Z., Marchand C., Weinstein J.N., Bathe O.F, & Liang H. (2018). Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell reports, 23(1), 255-269.e4.
+ Open protocol
+ Expand
2

Lentiviral Transduction for Gene Knockdown

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lentiviruses were produced by co-transfection HEK293LTX cells with the MISSION® TRC2 pLKO.5-puro Non-Mammalian shRNA Control Plasmid DNA or with the pLKO-puro shRNA constructs (Sigma, shRNA sequences are available in Table S3) and the Lentiviral Packaging Mix (psPAX2 and pMD2.G). U2OS and NCIH1975 cells were transduced by the lentivirus, and cells with stable knockdowns were selected using puromycin (2 μg/ml for U2OS and 1 μg/ml for NCIH1975). The knockdown of RUNX1 and SNAI1 in stable cell lines was confirmed by quantitative real-time PCR.
Peng X., Chen Z., Farshidfar F., Xu X., Lorenzi P.L., Wang Y., Cheng F., Tan L., Mojumdar K., Du D., Ge Z., Li J., Thomas G.V., Birsoy K., Liu L., Zhang H., Zhao Z., Marchand C., Weinstein J.N., Bathe O.F, & Liang H. (2018). Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell reports, 23(1), 255-269.e4.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!